RTOG Foundation Study 3505

Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer

Principal Investigator

David E. Gerber, MD

Primary Objective

To compare the overall survival (OS) for patients with Stage III unresectable non-small cell lung cancer treated with or without nivolumab following concurrent chemoradiation.

Patient Population

Patients with Stage IIIA or stage IIIB pathologically proven NSCLC with unresectable, medically inoperable disease, or patients who refuse resection.

Study Results

This study was terminated early due to the reporting of another study which changed this population's standard of care and rendered the control arm obsolete. Eight of the planned 550 analyzable participants were enrolled at the time of termination. No publication was generated for this study due to its early termination. Study results are posted on ClinicalTrials.gov.